
## **Bertrand Godeau**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5278587/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immunity, 2022, 55, 1096-1104.e4.	14.3	42
2	Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia. Science Translational Medicine, 2021, 13, .	12.4	40
3	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity, 2021, 54, 2893-2907.e5.	14.3	107
4	Longâ€term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITPâ€ritux. American Journal of Hematology, 2019, 94, 1314-1324.	4.1	55
5	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity, 2015, 62, 22-30.	6.5	40
6	Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood, 2014, 124, 3228-3236.	1.4	142
7	B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. Journal of Clinical Investigation, 2013, 123, 432-442.	8.2	154
8	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood, 2012, 119, 5989-5995.	1.4	284
9	Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood, 2009, 113, 2386-2393.	1.4	2,128